Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Imugene Ltd (IMU AU)
Watchlist
65
Analysis
Health Care
•
Australia
Imugene Limited is a health biotechnology development company. The Company manufactures vaccines for gastric and breast cancer treatments. Imugene operates in Europe and Australia.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Imugene Ltd
•
13 Jan 2025 00:30
Imugene (IMU AU): Pipeline Progresses; Capital Injection to Extend Cash Runway to Late 2025
Imugene dosed first Australian patient in Phase 1b trial for azer-cel in DLBCL. Azer-cel has potential to become blockbuster drug. Company plans...
Tina Banerjee
Follow
376 Views
Share
bullish
•
Thematic (Sector/Industry)
•
20 Jul 2025 00:30
APAC Healthcare Weekly (July 20) – Henlius Bio, CanSino, Nippon Shinyaku, JCR, Mesoblast, Sun Pharma
Henlius Bio initiates P3 U.S. trial for cancer drug. FDA rejected Nippon Shinyaku’s new drug filing. JCR partners with Acumen to develop...
Tina Banerjee
Follow
499 Views
Share
bullish
•
National Storage REIT
•
13 Jul 2025 23:00
•
Syndicated
National Storage REIT - The Monday Report - 14 July 2025
Wrap of events affecting the market on Friday night and the weekend and a preview of the week ahead
FNArena
Follow
170 Views
Share
bullish
•
Thematic (Sector/Industry)
•
29 Jun 2025 00:30
APAC Healthcare Weekly (June 29)- RemeGen, Innovent, Daiichi, SanBio, Otsuka, Chugai, Glenmark
Last week couple of Chinese companies signed outlicensing deals with international players. Innovent got weight loss drug approval in China....
Tina Banerjee
Follow
483 Views
Share
bullish
•
Thematic (Sector/Industry)
•
08 Jun 2025 00:30
APAC Healthcare Weekly (June 8)- Hansoh Pharma, Daiichi Sankyo, Takeda, Mayne Pharma, Zydus Life
Hansoh stuck deal with Regeneron for obesity drug candidate. Daiichi Sankyo unveiled positive phase 3 trial result in first-line breast cancer....
Tina Banerjee
Follow
669 Views
Share
1
2
3
4
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.4
x